Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination
- 7 March 2005
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 102 (11) , 4185-4190
Abstract
Active suppression of tumor-specific T lymphocytes can limit the immune-mediated destruction of cancer cells. Of the various strategies used by tumors to counteract immune attacks, myeloid suppressors recruited by growing cancers are particularly efficient, often resulting in the induction of systemic T lymphocyte dysfunction. We have previously shown that the mechanism by which myeloid cells from tumor-bearing hosts block immune defense strategies involves two enzymes that metabolizel-arginine: arginase and nitric oxide (NO) synthase. NO-releasing aspirin is a classic aspirin molecule covalently linked to a NO donor group. NO aspirin does not possess direct antitumor activity. However, by interfering with the inhibitory enzymatic activities of myeloid cells, orally administered NO aspirin normalized the immune status of tumor-bearing hosts, increased the number and function of tumor-antigen-specific T lymphocytes, and enhanced the preventive and therapeutic effectiveness of the antitumor immunity elicited by cancer vaccination. Because cancer vaccines and NO aspirin are currently being investigated in independent phase I/II clinical trials, these findings offer a rationale to combine these treatments in subjects with advanced neoplastic diseases.Keywords
This publication has 43 references indexed in Scilit:
- Cancer immunotherapy: moving beyond current vaccinesNature Medicine, 2004
- TCR ζ-chain downregulation: curtailing an excessive inflammatory immune responseNature Reviews Immunology, 2004
- Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell ResponsesCancer Research, 2004
- NO-donating aspirin inhibits intestinal carcinogenesis in Min (APCMin/+) miceBiochemical and Biophysical Research Communications, 2004
- Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor ImmunosurveillanceJournal of Experimental Medicine, 2003
- Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary CarcinomaJournal of Experimental Medicine, 2003
- Derangement of immune responses by myeloid suppressor cellsCancer Immunology, Immunotherapy, 2003
- Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivityBlood, 2003
- Peroxynitrite: reactive, invasive and enigmaticCurrent Opinion in Chemical Biology, 1999
- Effect of a new non‐steroidal anti‐inflammatory drug, nitroflurbiprofen, on the expression of inducible nitric oxide synthase in rat neutrophilsBritish Journal of Pharmacology, 1995